{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:45:59Z","timestamp":1789677959924,"version":"4.0.1"},"reference-count":193,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.prp.2026.156658","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:07:20Z","timestamp":1786374440000},"page":"156658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Reprogramming tumor-associated macrophages and interferon-gamma signaling to overcome therapeutic resistance in cancer"],"prefix":"10.1016","volume":"287","author":[{"given":"HongMei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2026.156658_bib1","doi-asserted-by":"crossref","DOI":"10.4110\/in.2026.26.e11","article-title":"Tumor cells as architects of immune refractoriness: dismantling intrinsic programs of tumor cells for clinical translation","volume":"26","author":"Lee","year":"2026","journal-title":"Immune Netw."},{"issue":"5","key":"10.1016\/j.prp.2026.156658_bib2","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41423-026-01405-y","article-title":"T cell adaptation in chronic infections and tumors","volume":"23","author":"Luxenburger","year":"2026","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.prp.2026.156658_bib4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156658_bib5","first-page":"21","article-title":"Preclinical nanoparticle approaches targeting tumor-associated macrophages in breast cancer: from mechanisms to therapeutic strategies","author":"Teng","year":"2026","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.prp.2026.156658_bib6","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","article-title":"A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells","volume":"184","author":"Cheng","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.prp.2026.156658_bib7","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cell.2019.03.005","article-title":"A single-cell atlas of the tumor and immune ecosystem of human breast cancer","volume":"177","author":"Wagner","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.prp.2026.156658_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2026.1774215","article-title":"Spatiotemporal and metabolic heterogeneity of tumor-associated macrophages in glioblastoma: from single-cell insights to therapeutic targeting","volume":"14","author":"Lu","year":"2026","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.prp.2026.156658_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1816086","article-title":"Immune architecture of colorectal cancer brain metastases: spatial TAM heterogeneity and PD-L1 dynamics","volume":"17","author":"Grape","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib10","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell. Rep."},{"key":"10.1016\/j.prp.2026.156658_bib11","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.prp.2026.156658_bib12","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"New. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.prp.2026.156658_bib13","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/s41467-025-67964-2","article-title":"Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers","volume":"17","author":"Pedroza","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2026.156658_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1726329","article-title":"Chimeric antigen receptor macrophages therapy for glioblastoma: challenges and opportunities from preclinical evidence to clinical translation","volume":"17","author":"Zhai","year":"2026","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2026.156658_bib15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11060-026-05497-4","article-title":"Endogenous immune recruitment in glioblastoma CAR T therapy: cytokine, myeloid, and chemokine circuitry","volume":"177","author":"Liu","year":"2026","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.prp.2026.156658_bib16","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","article-title":"The complex role of tumor-infiltrating macrophages","volume":"23","author":"Christofides","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib17","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/228620a0","article-title":"Cooperation of immune lymphoid cells with macrophages in tumour immunity","volume":"228","author":"Evans","year":"1970","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156658_bib18","doi-asserted-by":"crossref","first-page":"6166","DOI":"10.4049\/jimmunol.164.12.6166","article-title":"M-1\/M-2 macrophages and the Th1\/Th2 paradigm","volume":"164","author":"Mills","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050946","article-title":"Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.prp.2026.156658_bib20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib21","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","article-title":"Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy","volume":"25","author":"Ries","year":"2014","journal-title":"Cancer Cell."},{"key":"10.1016\/j.prp.2026.156658_bib22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib23","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ccell.2024.12.008","article-title":"A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer","volume":"43","author":"Acha-Sagredo","year":"2025","journal-title":"Cancer Cell."},{"key":"10.1016\/j.prp.2026.156658_bib24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell."},{"key":"10.1016\/j.prp.2026.156658_bib25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","article-title":"Targeting tumor-associated macrophages to synergize tumor immunotherapy","volume":"6","author":"Xiang","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.prp.2026.156658_bib26","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.3390\/cells10113194","article-title":"Macrophage reprogramming and cancer therapeutics: role of iNOS-derived NO","volume":"10","author":"Kashfi","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.prp.2026.156658_bib27","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3389\/fimmu.2016.00626","article-title":"IL-6 improves the nitric oxide-induced cytotoxic CD8+ T cell dysfunction in human Chagas disease","volume":"7","author":"Sanmarco","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib28","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1172\/JCI45862","article-title":"Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice","volume":"121","author":"Lu","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.prp.2026.156658_bib29","article-title":"Tumor-associated CD8+T cell tolerance induced by erythroid progenitor cells","volume":"15","author":"Fan","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib30","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41416-018-0258-8","article-title":"Harnessing the immune system in glioblastoma","volume":"119","author":"Brown","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2026.156658_bib31","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/cmi.2017.143","article-title":"IDO1 in cancer: a Gemini of immune checkpoints","volume":"15","author":"Zhai","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib32","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12964-022-00909-0","article-title":"Reprogramming of glutamine metabolism and its impact on immune response in the tumor microenvironment","volume":"20","author":"Ma","year":"2022","journal-title":"Cell. Commun. Signal."},{"key":"10.1016\/j.prp.2026.156658_bib33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jare.2024.02.009","article-title":"Targeting lipid metabolism of macrophages: A new strategy for tumor therapy","volume":"68","author":"Shao","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.prp.2026.156658_bib34","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2085432","article-title":"Lipid-associated macrophages in the tumor-adipose microenvironment facilitate breast cancer progression","volume":"11","author":"Liu","year":"2022","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.prp.2026.156658_bib35","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1007\/s00262-022-03173-w","article-title":"Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer","volume":"71","author":"Zhang","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.prp.2026.156658_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.seminoncol.2026.152495","article-title":"Targeting TREM2+tumor-associated macrophages reactivates antitumor immunity and improves anti-PD-1 efficacy in gastric cancer","volume":"53","author":"Xu","year":"2026","journal-title":"Semin. Oncol."},{"issue":"886-900","key":"10.1016\/j.prp.2026.156658_bib37","article-title":"TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy","volume":"182","author":"Molgora","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.prp.2026.156658_bib38","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00018-023-05099-7","article-title":"Wnt\/\u03b2-catenin-driven EMT regulation in human cancers","volume":"81","author":"Xue","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.prp.2026.156658_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.590941","article-title":"The crosstalk between tumor-associated macrophages (TAMs) and tumor cells and the corresponding targeted therapy","volume":"10","author":"Ge","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2026.156658_bib40","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12885-021-07898-2","article-title":"Activation of WNT7b autocrine eases metastasis of colorectal cancer via epithelial to mesenchymal transition and predicts poor prognosis","volume":"21","author":"Jiang","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prp.2026.156658_bib41","doi-asserted-by":"crossref","first-page":"6053","DOI":"10.1038\/s41598-024-56681-3","article-title":"Interferon-\u03b3 in the tumor microenvironment promotes the expression of B7H4 in colorectal cancer cells, thereby inhibiting cytotoxic T cells","volume":"14","author":"Jing","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2026.156658_bib42","first-page":"15","article-title":"The significance of the co-existence of osteopontin and tumor-associated macrophages in gastric cancer progression","author":"Lin","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prp.2026.156658_bib43","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.7150\/ijbs.15943","article-title":"Cyclooxygenase-2 in tumor-associated macrophages promotes metastatic potential of breast cancer cells through Akt pathway","volume":"12","author":"Gan","year":"2016","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.prp.2026.156658_bib44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jamcollsurg.2013.02.025","article-title":"Osteopontin up-regulates critical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype","volume":"217","author":"Li","year":"2013","journal-title":"J. Am. Coll. Surg."},{"key":"10.1016\/j.prp.2026.156658_bib45","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.7150\/ijms.56003","article-title":"The role of tumor-associated macrophages in primary hepatocellular carcinoma and its related targeting therapy","volume":"18","author":"Deng","year":"2021","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.prp.2026.156658_bib46","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1215\/S1152851704001115","article-title":"Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis","volume":"7","author":"Kaur","year":"2005","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.prp.2026.156658_bib47","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1158\/1078-0432.CCR-19-3890","article-title":"Macrophage HIF-1\u03b1 is an independent prognostic indicator in kidney cancer","volume":"26","author":"Cowman","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156658_bib48","doi-asserted-by":"crossref","first-page":"55043","DOI":"10.18632\/oncotarget.10393","article-title":"Adrenomedullin promotes the growth of pancreatic ductal adenocarcinoma through recruitment of myelomonocytic cells","volume":"7","author":"Xu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2026.156658_bib49","doi-asserted-by":"crossref","first-page":"7230","DOI":"10.1158\/1078-0432.CCR-11-1354","article-title":"Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in a paracrine and autocrine manner","volume":"17","author":"Chen","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156658_bib50","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.3390\/ijms26125552","article-title":"Adrenomedullin in Tumorigenesis and Cancer Progression","volume":"26","author":"Li","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156658_bib51","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1158\/0008-5472.CAN-22-2838","article-title":"Angiopoietin-2\u2013dependent spatial vascular destabilization promotes T-cell exclusion and limits immunotherapy in melanoma","volume":"83","author":"Park","year":"2023","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.prp.2026.156658_bib52","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-02064-1","article-title":"Decoding the spatiotemporal heterogeneity of tumor-associated macrophages","volume":"23","author":"Chu","year":"2024","journal-title":"Mol. Cancer"},{"issue":"815-832","key":"10.1016\/j.prp.2026.156658_bib53","article-title":"Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell."},{"issue":"1","key":"10.1016\/j.prp.2026.156658_bib54","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12890-023-02809-6","article-title":"Effects of IFN-\u03b3 on the immunological microenvironment and TAM polarity in stage IA non-small cell lung cancer and its mechanisms","volume":"24","author":"Zhao","year":"2024","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.prp.2026.156658_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.756225","article-title":"Immune evasion mechanism and AXL","volume":"11","author":"Son","year":"2021","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.prp.2026.156658_bib56","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41423-024-01232-z","article-title":"Targeting of TAMs: can we be more clever than cancer cells","volume":"21","author":"Kzhyshkowska","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib57","article-title":"CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1\/CTLA-4 bispecific antibody in patients with solid tumors","author":"Wang","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.prp.2026.156658_bib58","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1158\/0008-5472.CAN-22-2841","article-title":"CCR2+ monocyte-derived macrophages influence trajectories of acquired therapy resistance in Braf-mutant melanoma","volume":"83","author":"Kim","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2026.156658_bib59","article-title":"The paradoxical role of IFN-\u03b3 in cancer: balancing immune activation and immune evasion","author":"Liu","year":"2025","journal-title":"Pathol. -Res. Pract."},{"issue":"1","key":"10.1016\/j.prp.2026.156658_bib60","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.1038\/s41467-024-51496-2","article-title":"Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade","volume":"15","author":"Holzgruber","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2026.156658_bib61","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12943-025-02294-x","article-title":"Dual role of interferon-gamma in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors","volume":"24","author":"Wawrzyniak","year":"2025","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2026.156658_bib62","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1038\/s41467-022-32754-7","article-title":"Selective suppression of melanoma lacking IFN-\u03b3 pathway by JAK inhibition depends on T cells and host TNF signaling","volume":"13","author":"Shen","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2026.156658_bib63","article-title":"The role of B2M in cancer immunotherapy resistance: function, resistance mechanism, and reversal strategies","volume":"16","author":"Han","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.727987","article-title":"SOCS proteins in immunity, inflammatory diseases, and immune-related cancer","volume":"8","author":"Sobah","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.prp.2026.156658_bib65","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1042\/EBC20230001","article-title":"The role of IFN-\u03b3-signalling in response to immune checkpoint blockade therapy","volume":"67","author":"Wong","year":"2023","journal-title":"Essays Biochem."},{"key":"10.1016\/j.prp.2026.156658_bib66","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1038\/s41467-019-11147-3","article-title":"IFN-\u03b3 selectively suppresses a subset of TLR4-activated genes and enhancers to potentiate macrophage activation","volume":"10","author":"Kang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2026.156658_bib67","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/jmcb\/mjw042","article-title":"SENP1 regulates IFN-\u03b3\u2212 STAT1 signaling through STAT3\u2212 SOCS3 negative feedback loop","volume":"9","author":"Yu","year":"2017","journal-title":"J. Mol. Cell. Biol."},{"key":"10.1016\/j.prp.2026.156658_bib68","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2172-10-10","article-title":"ER stress affects processing of MHC class I-associated peptides","volume":"10","author":"Granados","year":"2009","journal-title":"BMC Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib69","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s13046-024-03180-y","article-title":"Combining ERAP1 silencing and entinostat therapy to overcome resistance to cancer immunotherapy in neuroblastoma","volume":"43","author":"Tempora","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156658_bib70","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00262-019-02358-0","article-title":"Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1)","volume":"68","author":"Koumantou","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.prp.2026.156658_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1066483","article-title":"ERAP1 and ERAP2, synergize to self-modulate their respective activities","volume":"13","author":"Mart\u00edn-Esteban","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib72","first-page":"28","article-title":"Epigenomic landscapes define differential Janus kinases inhibitor sensitivity in IFN-\u03b3-primed human macrophages","author":"Kwon","year":"2025","journal-title":"IScience"},{"key":"10.1016\/j.prp.2026.156658_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107588","article-title":"Metabolic and epigenetic regulation of macrophage polarization in atherosclerosis: Molecular mechanisms and targeted therapies","author":"Yang","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.prp.2026.156658_bib74","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41423-019-0315-0","article-title":"Epigenetic regulation of macrophages: from homeostasis maintenance to host defense","volume":"17","author":"Chen","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib75","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1038\/s41467-020-16158-z","article-title":"Sakamuri SSVP, et al. Distinct fate, dynamics and niches of renal macrophages of bone marrow or embryonic origins","volume":"11","author":"Liu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2026.156658_bib76","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.3390\/cells10112826","article-title":"Modulation of immune components on stem cell and dormancy in cancer","volume":"10","author":"Jiang","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.prp.2026.156658_bib77","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.179017","article-title":"The STAT3\/SETDB2 axis dictates NF-\u03baB\u2013mediated inflammation in macrophages during wound repair","volume":"9","author":"Mangum","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.prp.2026.156658_bib78","article-title":"Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators","volume":"4","author":"Pastore","year":"2022","journal-title":"JHEP Rep."},{"key":"10.1016\/j.prp.2026.156658_bib79","doi-asserted-by":"crossref","first-page":"73003","DOI":"10.18632\/oncotarget.12193","article-title":"Elevated level of interleukin-35 in colorectal cancer induces conversion of T cells into iTr35 by activating STAT1\/STAT3","volume":"7","author":"Ma","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2026.156658_bib80","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s10238-025-01562-w","article-title":"Harnessing IL-27: challenges and potential in cancer immunotherapy","volume":"25","author":"Maleki","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.prp.2026.156658_bib81","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/vaccines13020182","article-title":"HDAC3: A Multifaceted Modulator in Immunotherapy Sensitization","volume":"13","author":"Han","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.prp.2026.156658_bib82","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.66014","article-title":"Competitive binding of STATs to receptor phospho-Tyr motifs accounts for altered cytokine responses","volume":"10","author":"Wilmes","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.prp.2026.156658_bib83","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2412990122","article-title":"An atlas of protein phosphorylation dynamics during interferon signaling","volume":"122","author":"Busnadiego","year":"2025","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.prp.2026.156658_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.736670","article-title":"High endothelial venules: a vascular perspective on tertiary lymphoid structures in cancer","volume":"12","author":"Vella","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib85","doi-asserted-by":"crossref","unstructured":"Liu S.-X., Wu T.-W., Luo D.-H., Zhang L.-L., Zhou L., Luo Y.-L., et al. Interferon-responsive HEVs drive tumor tertiary lymphoid structure formation and predict immunotherapy response in nasopharyngeal carcinoma. Cell Rep Med 2025.","DOI":"10.1016\/j.xcrm.2025.102200"},{"key":"10.1016\/j.prp.2026.156658_bib86","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41467-023-35948-9","article-title":"IFN\u03b3 signaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity of intra-tumoral stem-like T cells","volume":"14","author":"Mazet","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2026.156658_bib87","first-page":"43","article-title":"Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction","volume":"4","author":"Qiu","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.prp.2026.156658_bib88","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.3390\/cancers17152547","article-title":"IFN \u03b3 and the IFN \u03b3 Signaling Pathways in Merkel Cell Carcinoma","volume":"17","author":"Song","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2026.156658_bib89","article-title":"Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib90","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s43018-023-00522-1","article-title":"Disrupting the phase separation of KAT8\u2013IRF1 diminishes PD-L1 expression and promotes antitumor immunity","volume":"4","author":"Wu","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.prp.2026.156658_bib91","article-title":"Histone modifications and metabolic reprogramming in tumor-associated macrophages: a potential target of tumor immunotherapy","volume":"16","author":"Xu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2024.04.006","article-title":"Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma","volume":"57","author":"De Leo","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.prp.2026.156658_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1684836","article-title":"Macrophage TRIM21 lactylation exacerbates infection-induced orchitis through enhancing STAT1-mediated CXCL9 and CXCL10 production","volume":"16","author":"Tang","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1573039","article-title":"Lactate-mediated metabolic reprogramming of tumor-associated macrophages: implications for tumor progression and therapeutic potential","volume":"16","author":"Jin","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105502","article-title":"Histone lactylation in macrophage biology and disease: from plasticity regulation to therapeutic implications","volume":"111","author":"Bao","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.prp.2026.156658_bib96","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1016\/j.celrep.2016.08.051","article-title":"IFN-\u03b3 Induces Histone 3 Lysine 27 Trimethylation in a Small Subset of Promoters to Stably Silence Gene Expression in Human Macrophages","volume":"16","author":"Qiao","year":"2016","journal-title":"Cell. Rep."},{"key":"10.1016\/j.prp.2026.156658_bib97","first-page":"223","article-title":"IFN\u03b3-induced memory in human macrophages is sustained by the durability of cytokine signaling itself","author":"Gorin","year":"2026","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.prp.2026.156658_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1384249","article-title":"Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments","volume":"15","author":"Feldman","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib99","doi-asserted-by":"crossref","first-page":"7378","DOI":"10.7150\/thno.113727","article-title":"Focusing on the interplay between tumor-associated macrophages and tumor microenvironment: From mechanism to intervention","volume":"15","author":"Wu","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.prp.2026.156658_bib100","article-title":"Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment","volume":"12","author":"O\u2019Connell","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2026.156658_bib101","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2024941","article-title":"MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression","volume":"11","author":"Lin","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.prp.2026.156658_bib102","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12943-019-1022-2","article-title":"Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment","volume":"18","author":"Myers","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.prp.2026.156658_bib103","doi-asserted-by":"crossref","first-page":"3a","DOI":"10.1016\/j.bpj.2014.11.029","article-title":"Mitochondrial DNA stress primes the antiviral innate immune response","volume":"108","author":"West","year":"2015","journal-title":"Biophys. J."},{"key":"10.1016\/j.prp.2026.156658_bib104","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.cell.2014.11.036","article-title":"Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production","volume":"159","author":"White","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.prp.2026.156658_bib105","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells","volume":"539","author":"De Henau","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.prp.2026.156658_bib106","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-22-3313","article-title":"Eganelisib, a first-in-class PI3K\u03b3 inhibitor, in patients with advanced solid tumors: results of the phase 1\/1b MARIO-1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156658_bib107","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1136\/gutjnl-2024-333492","article-title":"Induction of macrophage efferocytosis in pancreatic cancer via PI3K\u03b3 inhibition and radiotherapy promotes tumour control","volume":"74","author":"Russell","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.prp.2026.156658_bib108","first-page":"144","article-title":"Progesterone and adiponectin receptor family member 3 expression and clinical significance in breast cancer tissues","volume":"22","author":"Dai","year":"2016","journal-title":"J. Hainan Med. Univ."},{"key":"10.1016\/j.prp.2026.156658_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116154","article-title":"Wnt signaling: Modulating tumor-associated macrophages and related immunotherapeutic insights","volume":"223","author":"Yuan","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.prp.2026.156658_bib110","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.3390\/cancers12113355","article-title":"Not all Wnt activation is equal: ligand-dependent versus ligand-independent Wnt activation in colorectal cancer","volume":"12","author":"Kleeman","year":"2020","journal-title":"Cancers"},{"issue":"25","key":"10.1016\/j.prp.2026.156658_bib111","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1038\/s41388-025-03365-5","article-title":"CDX2 downregulation regulates intrinsic WNT pathway activation, dictating metastasis in APC and CTNNB1 wildtype colorectal cancer","volume":"44","author":"Wouters","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2026.156658_bib112","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/\u03b2-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156658_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109071","article-title":"Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy","volume":"35","author":"DeVito","year":"2021","journal-title":"Cell. Rep."},{"key":"10.1016\/j.prp.2026.156658_bib114","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41392-025-02142-w","article-title":"Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances","volume":"10","author":"Xue","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.prp.2026.156658_bib115","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.prp.2026.156658_bib116","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13045-025-01678-2","article-title":"Anti-TGF-\u03b2\/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis","volume":"18","author":"Wu","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156658_bib117","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/s41467-026-69456-3","article-title":"Triple targeting of STING, TGF-\u03b2, and PD-L1 boosts CXCL16\u2013CXCR6 signaling for potent antitumor response","volume":"17","author":"Yi","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2026.156658_bib118","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3390\/genes15020197","article-title":"NF-\u03baB: governing macrophages in cancer","volume":"15","author":"Cornice","year":"2024","journal-title":"Genes"},{"key":"10.1016\/j.prp.2026.156658_bib119","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1384109","article-title":"Multiple functions of HMGB1 in cancer","volume":"14","author":"Lv","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2026.156658_bib120","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1336191","article-title":"HMGB1\/RAGE axis in tumor development: unraveling its significance","volume":"14","author":"Fan","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2026.156658_bib121","first-page":"12","article-title":"S100A9 and HMGB1 orchestrate MDSC-mediated immunosuppression in melanoma through TLR4 signaling","author":"\u00d6zbay Kurt","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.prp.2026.156658_bib122","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41416-024-02715-6","article-title":"Clinical landscape of macrophage-reprogramming cancer immunotherapies","volume":"131","author":"Rannikko","year":"2024","journal-title":"British Journal Cancer"},{"key":"10.1016\/j.prp.2026.156658_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1476030","article-title":"NF-\u03baB signaling pathway in tumor microenvironment","volume":"15","author":"Cao","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib124","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.7150\/jca.108194","article-title":"Nano-strategies for Targeting Tumor-Associated Macrophages in Cancer immunotherapy","volume":"16","author":"Li","year":"2025","journal-title":"J. Cancer"},{"key":"10.1016\/j.prp.2026.156658_bib125","article-title":"Novel insights into Notch signaling in tumor immunity: potential targets for cancer immunotherapy","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib126","first-page":"3","article-title":"Endothelial cell Notch signaling programs cancer-associated fibroblasts to promote tumor immune evasion. Res Sq","author":"Zhu","year":"2024","journal-title":"rs"},{"key":"10.1016\/j.prp.2026.156658_bib127","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccell.2017.01.007","article-title":"Endothelial Notch1 activity facilitates metastasis","volume":"31","author":"Wieland","year":"2017","journal-title":"Cancer Cell."},{"key":"10.1016\/j.prp.2026.156658_bib128","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3389\/fimmu.2018.00652","article-title":"Notch signaling in macrophages in the context of cancer immunity","volume":"9","author":"Palaga","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib129","doi-asserted-by":"crossref","first-page":"13603","DOI":"10.1038\/s41598-024-64375-z","article-title":"Notch signaling regulates UNC5B to suppress endothelial proliferation, migration, junction activity, and retinal plexus branching","volume":"14","author":"Raza","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2026.156658_bib130","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1158\/2326-6066.CIR-23-0037","article-title":"Notch signaling regulates immunosuppressive tumor-associated macrophage function in pancreatic cancer","volume":"12","author":"Yan","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.prp.2026.156658_bib131","first-page":"2026","article-title":"Tumor-associated macrophages promote chemoresistance to Paclitaxel via activating NOTCH2-JAG1 juxtacrine signaling","author":"Yu","year":"2026","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2026.156658_bib132","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1186\/s12885-022-10032-5","article-title":"Notch signaling mutations increase intra-tumor chemokine expression and predict response to immunotherapy in colorectal cancer","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prp.2026.156658_bib133","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/cac2.70021","article-title":"Immunosuppressive JAG2+ tumor-associated neutrophils hamper PD-1 blockade response in ovarian cancer by mediating the differentiation of effector regulatory T cells","volume":"45","author":"Wang","year":"2025","journal-title":"Cancer Commun."},{"key":"10.1016\/j.prp.2026.156658_bib134","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2147\/JIR.S394894","article-title":"Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer","volume":"16","author":"Lin","year":"2023","journal-title":"J. Inflamm. Res."},{"issue":"1","key":"10.1016\/j.prp.2026.156658_bib135","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s10238-025-01825-6","article-title":"Notch pathway defines an aggressive and immune-suppressive phenotype associated with checkpoint inhibitor resistance in pan-gastrointestinal adenocarcinomas","volume":"25","author":"Luo","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.prp.2026.156658_bib136","unstructured":"Administration USF and D. FDA approves pexidartinib for tenosynovial giant cell tumor 2021."},{"key":"10.1016\/j.prp.2026.156658_bib137","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/annonc\/mdz163","article-title":"Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced\/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages","volume":"30","author":"Gomez-Roca","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2026.156658_bib138","first-page":"3257","article-title":"Challenges and prospects of CSF1R targeting for advanced malignancies","volume":"13","author":"Moeller","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.prp.2026.156658_bib139","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.celrep.2018.03.131","article-title":"CSF1R+ macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype","volume":"23","author":"Candido","year":"2018","journal-title":"Cell. Rep."},{"key":"10.1016\/j.prp.2026.156658_bib140","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ccell.2017.10.005","article-title":"Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors","volume":"32","author":"Kumar","year":"2017","journal-title":"Cancer Cell."},{"key":"10.1016\/j.prp.2026.156658_bib141","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.7150\/thno.50683","article-title":"The twin cytokines interleukin-34 and CSF-1: masterful conductors of macrophage homeostasis","volume":"11","author":"Mu\u00f1oz-Garcia","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.prp.2026.156658_bib142","first-page":"10","article-title":"Function of CSF1 and IL34 in macrophage homeostasis, inflammation, and cancer","author":"Lin","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib143","first-page":"133","article-title":"Monocyte-neutrophil entanglement in glioblastoma","author":"Friedmann-Morvinski","year":"2023","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.prp.2026.156658_bib144","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s42003-026-09853-y","article-title":"An ontogeny-cytokine code determines macrophage response polarity and tumor outcomes","volume":"9","author":"Schaer","year":"2026","journal-title":"Commun. Biol."},{"key":"10.1016\/j.prp.2026.156658_bib145","doi-asserted-by":"crossref","first-page":"855","DOI":"10.7150\/jca.132006","article-title":"Myeloid-Derived Suppressor Cells and Radiotherapy: Regulation and Clinical Implications","volume":"17","author":"Yang","year":"2026","journal-title":"J. Cancer"},{"key":"10.1016\/j.prp.2026.156658_bib146","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2026.156658_bib147","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1715761","article-title":"Safety and immunologic impact of neoadjuvant\/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma","volume":"17","author":"Urman","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105522","article-title":"A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma","volume":"10","author":"Rosenbaum","year":"2025","journal-title":"ESMO Open."},{"key":"10.1016\/j.prp.2026.156658_bib149","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011170","article-title":"Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial","volume":"13","author":"Luke","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2026.156658_bib150","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.178146","article-title":"Sustained inhibition of CSF1R signaling augments antitumor immunity through inhibiting tumor-associated macrophages","volume":"10","author":"Sato","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.prp.2026.156658_bib151","doi-asserted-by":"crossref","unstructured":"Patnaik A., Hamilton E.P., Winer I.S., Tan W., Hubbard J.M., Schenk E.L., et al. A phase 1a dose-escalation study of PY314, a TREM2 (Triggering Receptor Expressed on Macrophages 2) targeting monoclonal antibody. 2022.","DOI":"10.1200\/JCO.2022.40.16_suppl.2648"},{"issue":"5","key":"10.1016\/j.prp.2026.156658_bib152","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41423-026-01411-0","article-title":"Lipid metabolism reprogramming shapes the immune landscape in the tumor microenvironment","volume":"23","author":"Du","year":"2026","journal-title":"Cell. Mol.Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib153","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s40364-024-00675-w","article-title":"The double-edged role and therapeutic potential of TREM2 in atherosclerosis","volume":"12","author":"Zhu","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.prp.2026.156658_bib154","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.tem.2024.04.009","article-title":"Lipid-associated macrophages between aggravation and alleviation of metabolic diseases","volume":"35","author":"Xu","year":"2024","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.prp.2026.156658_bib155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1495853","article-title":"Lipid metabolism in myeloid cell function and chronic inflammatory diseases","volume":"15","author":"Ito","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2026.156658_bib156","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41698-025-01152-9","article-title":"TREM2-mediated regulation of myeloid cells in the tumor microenvironment: new insights and therapeutic prospects","volume":"9","author":"Huang","year":"2025","journal-title":"npj Precis. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156658_bib157","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.1038\/s41467-025-62132-y","article-title":"Metabolism archetype cancer cells induce protumor TREM2+ macrophages via oxLDL-mediated metabolic interplay in hepatocellular carcinoma","volume":"16","author":"Chu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2026.156658_bib158","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1200\/JCO.22.02604","article-title":"Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined with Azacitidine in Patients with Previously Untreated AML: Phase Ib Results","volume":"41","author":"Daver","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156658_bib159","unstructured":"Gilead. Gilead statement on discontinuation of phase 3 ENHANCE-3 study in AML 2024."},{"key":"10.1016\/j.prp.2026.156658_bib160","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40364-023-00456-x","article-title":"The landscape overview of CD47-based immunotherapy for hematological malignancies","volume":"11","author":"Yang","year":"2023","journal-title":"Biomark. Res."},{"key":"10.1016\/j.prp.2026.156658_bib161","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S1470-2045(21)00584-2","article-title":"Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study","volume":"22","author":"Lakhani","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.prp.2026.156658_bib162","doi-asserted-by":"crossref","DOI":"10.1002\/mog2.70030","article-title":"Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer Therapeutics","volume":"4","author":"Sun","year":"2025","journal-title":"MedComm\u2013Oncology"},{"key":"10.1016\/j.prp.2026.156658_bib163","first-page":"134","article-title":"Combining SiRP\u03b1 decoy\u2013coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells","author":"Stefanidis","year":"2024","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.prp.2026.156658_bib164","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1038\/s41467-020-18298-8","article-title":"Collagen promotes anti-PD-1\/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion","volume":"11","author":"Peng","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2026.156658_bib165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.929339","article-title":"Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages","volume":"13","author":"Zeller","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib166","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011030","article-title":"Targeting MARCO in combination with anti-CTLA-4 leads to enhanced melanoma regression and immune cell infiltration via macrophage reprogramming","volume":"13","author":"Takahashi","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2026.156658_bib167","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.4_suppl.332","article-title":"Final analysis of the randomized phase 2 part of the ASPEN-06 study: A phase 2\/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric\/gastroesophageal cancer (GC)","volume":"43","author":"Shitara","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2026.156658_bib168","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003091","article-title":"Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors","volume":"10","author":"Cristescu","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2026.156658_bib169","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176181","article-title":"Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion","volume":"12","author":"Albacker","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.prp.2026.156658_bib170","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/s41467-020-14290-4","article-title":"Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-\u03b3-signaling mutant cancer cells","volume":"11","author":"Williams","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2026.156658_bib171","first-page":"1","article-title":"Emapalumab treatment in rheumatologic disease-associated hemophagocytic lymphohistiocytosis: a plain language summary","author":"Chandrakasan","year":"2025","journal-title":"Immunotherapy"},{"key":"10.1016\/j.prp.2026.156658_bib172","first-page":"1783","article-title":"Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis. Blood","volume":"134","author":"Vallurupalli","year":"2019","journal-title":"J. Am. Soc. Hematol."},{"key":"10.1016\/j.prp.2026.156658_bib173","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1563736","article-title":"Case Report: Successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy","volume":"16","author":"Manghisi","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156658_bib174","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1543622","article-title":"Emapalumab for severe cytokine release syndrome in solid tumor CAR-T: a case report","volume":"15","author":"Ruemmele","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2026.156658_bib175","doi-asserted-by":"crossref","unstructured":"Pili R., Haas N.B., Monk P., Logan T.F., Narayan V., Burney H., et al. A phase I\/II study to evaluate the safety, pharmacodynamics, and efficacy of entinostat in combination with atezolizumab and bevacizumab in patients with renal cell carcinoma. 2023.","DOI":"10.1200\/JCO.2023.41.16_suppl.4526"},{"key":"10.1016\/j.prp.2026.156658_bib176","doi-asserted-by":"crossref","unstructured":"Efthymiadou A., Gu C., Wang C., Wang H., Li Z., Garcia-Irigoyen O., et al. Nonredundant roles of the HDAC3 corepressor complex subunits SMRT and NCOR in controlling inflammatory and metabolic macrophage pathways. BioRxiv 2025:2025.","DOI":"10.1101\/2025.05.13.653058"},{"key":"10.1016\/j.prp.2026.156658_bib177","doi-asserted-by":"crossref","unstructured":"Savardekar H., Stiff A., Liu A., Wesolowski R., Schwarz E., Garbarine I.C., et al. BRD4 inhibition leads to MDSC apoptosis and enhances checkpoint blockade therapy. J Clin Invest 2025.","DOI":"10.1172\/JCI181975"},{"key":"10.1016\/j.prp.2026.156658_bib178","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.prp.2026.156658_bib179","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s43682-025-00037-z","article-title":"Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma: a phase 2 clinical trial","volume":"5","author":"Hallab","year":"2025","journal-title":"Epigenet. Commun."},{"key":"10.1016\/j.prp.2026.156658_bib180","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1038\/s41416-023-02267-1","article-title":"Phase I\/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors","volume":"128","author":"Luke","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2026.156658_bib181","doi-asserted-by":"crossref","first-page":"417","DOI":"10.21873\/cdp.10455","article-title":"The Role of Axl Inhibition and Immune Checkpoint Blockade in Non-small Cell Lung Cancer: Current Understanding and Treatment Strategies","volume":"5","author":"Kim","year":"2025","journal-title":"Cancer Diagn. Progn."},{"issue":"4","key":"10.1016\/j.prp.2026.156658_bib182","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41416-018-0188-5","article-title":"STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer","volume":"119","author":"Ghaffari","year":"2018","journal-title":"British J. Cancer"},{"issue":"8","key":"10.1016\/j.prp.2026.156658_bib183","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41419-022-05123-x","article-title":"BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia","volume":"13","author":"Zhong","year":"2022","journal-title":"Cell Death Disease"},{"issue":"1","key":"10.1016\/j.prp.2026.156658_bib184","doi-asserted-by":"crossref","first-page":"13225","DOI":"10.1038\/s41598-018-31658-1","article-title":"Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells","volume":"8","author":"Ebine","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2026.156658_bib185","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1016\/j.ymthe.2022.07.022","article-title":"BET inhibition triggers antitumor immunity by enhancing MHC class I expression in head and neck squamous cell carcinoma","volume":"30","author":"Zhang","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.prp.2026.156658_bib186","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012991","article-title":"Spatial transcriptomic profiling of metastatic renal cell carcinoma identifies chemokine-driven macrophage and CD8+ T-cell interactions predictive of immunotherapy response","volume":"13","author":"Kalogirou","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2026.156658_bib187","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1158\/1078-0432.CCR-25-1201","article-title":"CAR-Macrophage Cell Therapy: A New Era of Hope for Pancreatic Cancer","volume":"31","author":"Wei","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2026.156658_bib188","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1016\/j.ymthe.2025.03.024","article-title":"Genetically engineered macrophages reverse the immunosuppressive tumor microenvironment and improve immunotherapeutic efficacy in TNBC","volume":"33","author":"Jiang","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.prp.2026.156658_bib189","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.3390\/diagnostics12122985","article-title":"The Potential Role of MUC16 (CA125) Biomarker in Lung Cancer: A Magic Biomarker but with Adversity","volume":"12","author":"Saad","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.prp.2026.156658_bib190","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.3390\/molecules26175163","article-title":"Impacting the remedial potential of nano delivery-based flavonoids for breast cancer treatment","volume":"26","author":"Sindhu","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.prp.2026.156658_bib191","doi-asserted-by":"crossref","DOI":"10.1016\/j.afres.2025.101132","article-title":"Roles of foods and related components: an overview on cancer causatives, and plausible preventions","volume":"5","author":"Mohammed","year":"2025","journal-title":"Appl. Food Res."},{"key":"10.1016\/j.prp.2026.156658_bib192","first-page":"12","article-title":"Functionalized SWCNTs@Ag-TiO2nanocomposites induce ROS-mediated apoptosis and autophagy in liver cancer cells","author":"Jabir","year":"2023","journal-title":"Nanotechnol. Rev."},{"key":"10.1016\/j.prp.2026.156658_bib193","article-title":"The possible role furin and furin inhibitors in endometrial adenocarcinoma: a narrative review","volume":"7","author":"Al-kuraishy","year":"2024","journal-title":"Cancer Rep."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826003110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826003110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T06:37:55Z","timestamp":1788763075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033826003110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":193,"alternative-id":["S0344033826003110"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156658","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reprogramming tumor-associated macrophages and interferon-gamma signaling to overcome therapeutic resistance in cancer","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156658","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156658"}}